Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma

NCT02273752 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT02273752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02273752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2014
Completion date
December 31, 2015
Enrollment
2 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor-positive breast cancer, gastrinoma, glucagonoma, her2-negative breast cancer, insulinoma, mucositis, oral complications, pancreatic polypeptide tumor, progesterone receptor-positive breast cancer, recurrent breast cancer, recurrent islet cell carcinoma, recurrent renal cell cancer, somatostatinoma, stage iii renal cell cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer, stage iv renal cell cancer